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the acute coronary syndromesPrimary percutaneous coronary intervention (pPCI) is the
preferred reperfusion therapy for patients with an ST-
segment elevation myocardial infarction (STEMI) when it
is performed as soon as possible after the first medical
contact.1 The PCI reperfusion approach remains superior to
immediate thrombolysis (TL), even when transfer to an
angioplasty center is necessary.2 Primary PCI is the
preferred treatment for patients in shock and for the pa-
tients with contraindications to thrombolysis. By contrast,
both the European Society of Cardiology (ESC) and ACC/
AHA guidelines for patients with non-STEMI recommend an
immediate invasive strategy within 2 h of presentation for
very high-risk patients, an early invasive strategy within
24 h in high risk patients and an invasive strategy within
72 h in intermediate risk patients. Finally, both ESC and
ACC/AHA also provide a 1A recommendation for the radial
approach in experienced centers.3
Despite these advantages, data from several national
registries and surveys indicate that the use of pPCI is not
universally implemented, and thrombolysis is still used in
many patients.4 Furthermore, a large proportion of patients
presenting with STEMI do not receive reperfusion therapy. A
survey by Peter Widimisky in 2008 indicated that patient
access to reperfusion therapy and the use of primary PCI or
thrombolysis vary considerably between European coun-
tries. Northern, western and central Europeans countries
use primary PCI for the majority of their STEMI patients.
Southern Europe and the Balkans still predominantly use
TL, and as a result, many patients are do not receive
reperfusion therapy.5
Greece participated in this European survey and provided
data from a large countrywide survey in the HELIOS study,
which was published in 2007. The HELIOS survey showed a
suboptimal pPCI implementation in Greece, which was also
documented in the same period of time in another five Eu-
ropean countries. The predominant reperfusion therapy wasPeer review under responsibility of Hellenic Cardiological
Society.
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receive reperfusion therapy.6
Considering both the above scientific evidence and
variation in the existing practice patterns around Europe,
the leadership of EuroPCR, EAPCI and ESC Working Group on
Acute Cardiac e Care launched the “STENT FOR LIFE” (SFL)
initiative.7
The SFL initiative has supported the implementation of
timely pPCI to reduce the mortality and morbidity of pa-
tients suffering from ACS. Greece became a member of the
SFL initiative in August 2009. In 2012, three years after
participating in the SFL coalition, there was a threefold
increase in the number of pPCI cases. This increase paral-
lels a dramatic decrease (44%) in the no reperfusion therapy
for STEMI. However, thrombolysis remains the predominant
reperfusion therapy for STEMI patients.8
In this issue of Hellenic Journal of Cardiology, the same
group of HELIOS investigators conducted the PHAETHON
study to provide contemporary data on the ACS prevalence
and management in Greece. According to the authors, the
centers were selected on the basis of reliably representing
and proportionally covering all geographical areas of
Greece. The PHAETHON study selected PCI and non-PCI
centers, academic and non-academic, as well as public and
private hospitals from rural and urban areas in the country.
The primary outcome of the study was an assessment of the
epidemiological characteristics, care and in-hospital mor-
tality of ACS patients in Greece.9 Although the findings of
the PHAETHON study are consistent with those of the STENT
FOR LIFE initiative, the following points should be
emphasized:
 As mentioned above, there was a clear increase in the
number of primary PCI procedures in recent years in
Greece. This progress in STEMI management was recon-
firmed in the “PHAETHON” study, which showed similar
and improved reperfusion rates with PPCI of 34% (39%
underwent coronary angiogram), and 44.5% underwent
fibrinolysis and only 16.5% did not receive reperfusion
therapy. The most important finding from theElsevier B.V. This is an open access article under the CC BY-NC-ND
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used in the majority of the patients with STEMI (78.5%),
while thrombolysis (TL) remains the dominant reperfu-
sion therapy in STEMI patients (44.5%). The finding that
only 16.5% did not receive reperfusion therapy is difficult
to interpret and requires more clarification in new reg-
istries. The results of the Widimisky et al. study chal-
lenge the general impression that TL is more suitable for
widespread use. The opposite appears to be true in
countries using TL as the dominant strategy where
reperfusion therapy is less commonly used for STEMI
patients.5
 The patient delay is the time from symptom onset to the
1st medical contact. In the “PHAETHON” study, the pa-
tient delay was 163 min, which is comparable to that
described in the stent for life initiative (140 min). The
observations in those studies (Phaethon and SFL) are
similar to the results in many European countries and
highlight areas of public awareness and education that
we must to improve. The “ACT NOW SAVE A LIFE”
campaign is running in Greece and other European
countries, and some preliminary results show improve-
ment in patient delays.
 The in-hospital mortality found in PHAETHON study
(1.63%) should be re-evaluated in larger registries with
adequate power and should discriminate the mortality
rate between the different ACS groups (STEMI-NSTEMI).
Based on in a meta-analysis, primary PCI was more
effective than fibrinolysis at reducing mortality, and this
finding was reflected in the recommendations.10 On the
other hand, mortality might be affected by multiple
unmeasured features of care, including the total
ischemic time, differences in the operator experience
and organizational measures.11 In the last report of the
reperfusion treatment in 37 ESC countries, the in-
hospital mortality for STEMI patients treated with pPCI
varied between 3.1 and 6.1%. However, the mortality
data depend on the population that is studied and the
methodologies for data collection. For example, the high
mortality rate of cardiogenic shock (50%), which is not
always reported in the registries, might impact the
mortality rate.12 As the authors comment, the low hos-
pital mortality observed in the PHAETHON study (1.63%),
might imply a small likelihood of selection bias and un-
reported or missed events.9
 Finally, the data from the hospital discharge and short
follow-up are very important. The small, but substantial,
percentage of patients with type 2 MI define a subgroup
of STEMI patients who should be followed with strict
secondary prevention instructions.
 In conclusion, the data from PHAETHON study, a multi-
center observational survey, demonstrate striking prog-
ress in PPCI utilization and a high percentage of
reperfusion therapy in Greece. Additionally, the survey
demonstrates the need for systematic use of large reg-
istries to evaluate ACS patient care. A major challenge
for improving reperfusion therapy and the prognosis of
ACS patients in Greece is the lack of systematic, accu-
rate data. In this field, the data from PHAETHON survey
are very important. The findings of this study demon-
strate an increase in pPCI utilization and highpercentage of reperfusion therapy in Greece. It is time
to turn our attention to the further development of ACS
networks, system-based measures and improved orga-
nization of regional and national health systems.References
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